Redeye updates on NextCell following its Q2 2026 report, which financially aligned closely to our projections. The quarter's key updates were the commercial launch with FUJIFILM Biosciences and the formal rebranding of ProTrans to NXTCL-T1D. The primary value driver in the case remains the one-year readout from the younger age cohort in the ongoing Phase II trial, expected in September. The stock currently screens as "Attractively Priced".
LÄS MER
